15 completed, 3 terminated, 3 unknown, 2 recruiting. 25 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 25 | Completed 15, Terminated 3, Unknown 3, Recruiting 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 4, Terminated 1, Unknown 1 |
Follow lanreotide: new trials by email Literature Review of lanreotide trials Research Report on lanreotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., Amino acid solution - Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) | Phase 3 | Recruiting | Grupo Espanol de Tumores Neuroendocrinos | 166 | 2025-06-12 | 2026-09-16 |
| Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula Biospecimen Collection, Distal Pancreatectomy, Lanreotide - Pancreatic Carcinoma, Pancreatic Neoplasm | Phase 3 | Recruiting | SWOG Cancer Research Network | 274 | 2025-05-09 | 2026-03-31 |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy RYZ101, Everolimus, Sunitinib - GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor | Phase 3 | Active not recruiting | RayzeBio, Inc. | 343 | 2022-03-24 | 2026-10-05 |
| Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome Telotristat Ethyl, Lanreotide - Small Intestinal NET, Carcinoid Heart Disease | Phase 3 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2020-04-01 | 2020-02-05 | |
| Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Gamma knife radiosurgery, Lanreotide 60Mg Solution for Injection - Acromegaly Due to Pituitary Adenoma | Phase 3 | Unknown | Samsung Medical Center | 90 | 2018-03-01 | 2018-03-01 |
| Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours Lanreotide (Autogel formulation), Placebo, Best Supportive Care - Neuroendocrine Tumors in Lung | Phase 3 | Terminated | Ipsen | 77 | 2017-03-06 | 2022-07-06 |
| A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) lanreotide, Placebo - Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours | Phase 2 / Phase 3 | Terminated | Federation Francophone de Cancerologie Digestive | 53 | 2015-01-01 | 2023-01-18 |
| Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Lanreotide Autogel®, Lanreotide Acetate - Acromegaly | Phase 3 | Completed | Ipsen | 128 | 2014-10-01 | 2019-01-29 |
| Lanreotide In Polycystic Kidney Disease Study Lanreotide, saline - Autosomal Dominant Polycystic Kidney Disease (ADPKD | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 159 | 2014-09-19 | 2026-04-08 |
| Study of Lanreotide to Treat Polycystic Kidney Disease Lanreotide - Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 3 | Unknown | University Medical Center Groningen | 300 | 2012-06-01 | 2017-05-23 |
| Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients Lanreotide, non steroidal anti androgens and LHRH-a, Non steroidal anti androgens and LHRH-a - Prostate Cancer | Phase 3 | Terminated | Ipsen | 3 | 2011-06-01 | 2019-11-22 |
| Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea lanreotide (Autogel formulation) - Diarrhea | Phase 2 / Phase 3 | Completed | Ipsen | 42 | 2009-07-01 | 2019-01-15 |
| An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Lanreotide, Placebo - Carcinoid Syndrome | Phase 3 | Completed | Ipsen | 115 | 2009-05-01 | 2022-10-14 |
| Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour lanreotide (Autogel formulation) - Non Functioning Entero-pancreatic Endocrine Tumour | Phase 3 | Completed | Ipsen | 89 | 2009-02-01 | 2022-10-12 |
| Open-Label Extension of LOCKCYST Trial lanreotide - Polycystic Liver Disease, Hepatomegaly | Phase 2 / Phase 3 | Unknown | Radboud University Medical Center | 54 | 2008-04-01 | 2008-11-13 |
| Lanreotide as Treatment of Polycystic Livers Placebo, Lanreotide - Polycystic Liver Disease, Hepatomegaly | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 38 | 2007-10-01 | 2009-02-17 |
| Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Somatuline Autogel (lanreotide acetate), Home administration - Acromegaly | Phase 3 | Completed | Ipsen | 59 | 2007-04-01 | 2020-11-20 |
| GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma Octreotide-LAR, Lanreotide Autogel, Locoregional treatments - Advanced Hepatocellular Carcinoma | Phase 2 / Phase 3 | Completed | Federico II University | 25 | 2007-04-01 | 2009-08-17 |
| Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients lanreotide (Autogel formulation), Pegvisomant - Acromegaly | Phase 3 | Completed | Ipsen | 125 | 2006-10-01 | 2022-09-27 |
| Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours lanreotide (Autogel formulation), Placebo - Endocrine Tumors | Phase 3 | Completed | Ipsen | 264 | 2006-06-01 | 2025-03-05 |
Showing 20 of 25. Sign in to see all of them.
Acromegaly (8) · Neuroendocrine Tumors (4) · Polycystic Kidney, Autosomal Dominant (3) · Polycystic liver disease (3) · Carcinoid Tumor (2) · Diarrhea (2) · Hepatomegaly (2) · Liver Diseases (2) · Polycystic Kidney Diseases (2) · Serotonin Syndrome (2) · Adenoma, Islet Cell (1) · Carcinoid Heart Disease (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Flushing (1)
Ipsen (14) · Radboud University Medical Center (2) · Assistance Publique - Hôpitaux de Paris (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Federation Francophone de Cancerologie Digestive (1) · Federico II University (1) · Grupo Espanol de Tumores Neuroendocrinos (1) · RayzeBio, Inc. (1) · SWOG Cancer Research Network (1) · Samsung Medical Center (1) · University Medical Center Groningen (1)
France (11) · Netherlands (9) · Belgium (8) · United States (8) · Italy (7) · Germany (6) · Spain (6) · United Kingdom (6) · Czechia (5) · Poland (4) · Denmark (3) · Austria (2) · Brazil (2) · Canada (2) · India (2)
Frederik Nevens, MD, PhD (2) · Loes van Keimpema, MSc (2) · Angela Lamarca (1) · Annamaria Colao, MD, PhD (1) · Come Lepage, Pr (1) · Eric Baudin Baudin, M.D., Ph.D. (1) · Jonathan G Sham (1) · Joost PH Drenth, MD, PhD (1) · Joost PH Drenth, PhD (1) · Juan Valle (1)
PMID 39356039, PMID 33052555, PMID 10207464, PMID 10517918, PMID 10573522, PMID 10811995, PMID 10984283, PMID 12066229, PMID 12198662, PMID 12540801, PMID 12591191, PMID 12759473, PMID 14762851, PMID 14974910, PMID 15246216, PMID 16953241, PMID 17589893, PMID 18248639, PMID 19542735, PMID 19639415, PMID 19898989, PMID 21086246, PMID 21148630, PMID 23109694, PMID 25014687, PMID 25408662, PMID 26743120, PMID 27214300, PMID 27423779, PMID 27995519, PMID 30422235, PMID 31022403, PMID 31754316, PMID 32366244, PMID 33779943, PMID 36087395, PMID 38753757, PMID 42320793, PMID 6087395, PMID 7568806, PMID 7758431, PMID 8213718, PMID 8635123, PMID 8675143, PMID 8709253, PMID 8903411, PMID 8938543, PMID 9438850, PMID 9593409, PMID 9797392
2005 (2), 2004 (1), 2008 (1), 2009 (1), 2015 (1), UG1CA189974 (1)